source
- Zealand Pharma sells its rights to Takeda's rusfertide for $100 million ahead of FDA decisionZealand Pharma has agreed to sell its economic interest in rusfertide, a peptide drug being developed by Takeda and Protagonist Therapeutics, for $100 million. The transaction comes as the FDA rev…
- European trade group urges authorities to grant notified bodies access to Eudamed for risk-based oversightA trade association representing notified bodies has formally asked EU regulators to allow them to access the Eudamed database. The group says that such access would enable them to apply the risk-…